{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:10:52Z","timestamp":1790741452867,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Ministry of Education and Science | Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["FCT\/UIDB&P\/4950\/2025"],"award-info":[{"award-number":["FCT\/UIDB&P\/4950\/2025"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-00820-y","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T22:43:26Z","timestamp":1744238606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improvements induced by retinal gene therapy with voretigene neparvovec depend on visual cortical hemispheric dominance mechanisms"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2911-7993","authenticated-orcid":false,"given":"Mariana","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-0483","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Raimundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Quental","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-6373","authenticated-orcid":false,"given":"Miguel","family":"Castelo-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"820_CR1","doi-asserted-by":"publisher","first-page":"120ra15","DOI":"10.1126\/scitranslmed.3002865","volume":"4","author":"J Bennett","year":"2012","unstructured":"Bennett, J. et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci. Transl. Med. 4, 120ra15 (2012).","journal-title":"Sci. Transl. Med."},{"key":"820_CR2","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1172\/JCI57377","volume":"121","author":"M Ashtari","year":"2011","unstructured":"Ashtari, M. et al. The human visual cortex responds to gene therapy\u2013mediated recovery of retinal function. J. Clin. Investig. 121, 2160 (2011).","journal-title":"J. Clin. Investig."},{"key":"820_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.preteyeres.2008.05.003","volume":"27","author":"AI den Hollander","year":"2008","unstructured":"den Hollander, A. I., Roepman, R., Koenekoop, R. K. & Cremers, F. P. M. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog. Retin. Eye Res. 27, 391\u2013419 (2008).","journal-title":"Prog. Retin. Eye Res."},{"key":"820_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ymthe.2017.09.014","volume":"26","author":"G Le Meur","year":"2018","unstructured":"Le Meur, G. et al. Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis. Mol. Ther. 26, 256 (2018).","journal-title":"Mol. Ther."},{"key":"820_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/gt.2012.63","volume":"20","author":"FM Mowat","year":"2012","unstructured":"Mowat, F. M. et al. RPE65 gene therapy slows cone loss in Rpe65-deficient dogs. Gene Ther. 20, 545\u2013555 (2012). 2013 20:5.","journal-title":"Gene Ther."},{"key":"820_CR6","first-page":"480","volume":"10","author":"W Sharif","year":"2017","unstructured":"Sharif, W. & Sharif, Z. Leber\u2019s congenital amaurosis and the role of gene therapy in congenital retinal disorders. Int. J. Ophthalmol. 10, 480 (2017).","journal-title":"Int. J. Ophthalmol."},{"key":"820_CR7","doi-asserted-by":"publisher","unstructured":"Wang X., Yu C., Tzekov R. T., Zhu Y., Li W. The effect of human gene therapy for RPE65-associated Leber\u2019s congenital amaurosis on visual function: a systematic review and meta-analysis. Orphanet J. Rare Dis. 15,1\u20139. https:\/\/doi.org\/10.1186\/S13023-020-1304-1\/FIGURES\/5 (2020).","DOI":"10.1186\/S13023-020-1304-1\/FIGURES\/5"},{"key":"820_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3341\/kjo.2023.0008","volume":"37","author":"J Han","year":"2023","unstructured":"Han, J. et al. Voretigene neparvovec for the treatment of RPE65-associated retinal dystrophy: consensus and recommendations from the Korea RPE65-IRD Consensus Paper Committee. Korean J. Ophthalmol. 37, 166 (2023).","journal-title":"Korean J. Ophthalmol."},{"key":"820_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00417-012-2028-2","volume":"250","author":"RB Hufnagel","year":"2012","unstructured":"Hufnagel, R. B., Ahmed, Z. M., Corr\u00eaa, Z. M. & Sisk, R. A. Gene therapy for Leber congenital amaurosis advances and future directions. Graefes Arch. Clin. Exp. Ophthalmol. 250, 1117 (2012).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"820_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390, 849 (2017).","journal-title":"Lancet"},{"key":"820_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/ng0501-92","volume":"28","author":"GM Acland","year":"2001","unstructured":"Acland, G. M. et al. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28, 92\u201395 (2001).","journal-title":"Nat. Genet."},{"key":"820_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","volume":"130","author":"SG Jacobson","year":"2012","unstructured":"Jacobson, S. G. et al. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol. 130, 9\u201324 (2012).","journal-title":"Arch. Ophthalmol."},{"key":"820_CR13","unstructured":"FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss | FDA 2017. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss (accessed 29 Aug 2023)."},{"key":"820_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40291-020-00475-6","volume":"24","author":"C Kang","year":"2020","unstructured":"Kang, C. & Scott, L. J. Voretigene neparvovec: a review in RPE65 mutation-associated inherited retinal dystrophy. Mol. Diagn. Ther. 24, 487\u2013495 (2020).","journal-title":"Mol. Diagn. Ther."},{"key":"820_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","volume":"6","author":"WS Gange","year":"2022","unstructured":"Gange, W. S. et al. Perifoveal chorioretinal atrophy after subretinal voretigene Neparvovec-rzyl for RPE65-mediated leber congenital amaurosis. Ophthalmol. Retin. 6, 58\u201364 (2022).","journal-title":"Ophthalmol. Retin."},{"key":"820_CR16","doi-asserted-by":"publisher","unstructured":"Stingl K. et al. Therapy with voretigene neparvovec. How to measure success? Prog. Retin. Eye Res. 92. https:\/\/doi.org\/10.1016\/j.preteyeres.2022.101115 (2023).","DOI":"10.1016\/j.preteyeres.2022.101115"},{"key":"820_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/13816810802626399","volume":"30","author":"X Cai","year":"2009","unstructured":"Cai, X., Conley, S. M. & Naash, M. I. RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet. 30, 57\u201362 (2009).","journal-title":"Ophthalmic Genet."},{"key":"820_CR18","doi-asserted-by":"publisher","unstructured":"Marques J. P. et al. Design, development and deployment of a web-based interoperable registry for inherited retinal dystrophies in Portugal: the IRD-PT. Orphanet J. Rare Dis. 15, https:\/\/doi.org\/10.1186\/S13023-020-01591-6 (2020).","DOI":"10.1186\/S13023-020-01591-6"},{"key":"820_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/APO.0000000000000431","volume":"11","author":"JP Marques","year":"2022","unstructured":"Marques, J. P., Alfaiate, M. & Figueira, J. P. Subretinal Bleb of Voretigene Neparvovec. Asia Pac. J. Ophthalmol. 11, 211, https:\/\/doi.org\/10.1097\/APO.0000000000000431 (2022).","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"820_CR20","unstructured":"DiagnosysFST \u00ae Upgrade Module leading the wave 2021."},{"key":"820_CR21","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1167\/iovs.17-22321","volume":"59","author":"\u00c2SC Miranda","year":"2018","unstructured":"Miranda, \u00c2. S. C. et al. Optical properties influence visual cortical functional resolution after cataract surgery and both dissociate from subjectively perceived quality of vision. Investig. Ophthalmol. Vis. Sci. 59, 986\u2013994 (2018).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"820_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/cercor\/bhaa246","volume":"31","author":"M Rosenke","year":"2021","unstructured":"Rosenke, M., Van Hoof, R., Van Den Hurk, J., Grill-Spector, K. & Goebel, R. A probabilistic functional atlas of human occipito-temporal visual cortex. Cereb. Cortex 31, 603\u2013619 (2021).","journal-title":"Cereb. Cortex"},{"key":"820_CR23","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1007\/s00429-021-02338-0","volume":"226","author":"MF Silva","year":"2021","unstructured":"Silva, M. F. et al. Simultaneous changes in visual acuity, cortical population receptive field size, visual field map size, and retinal thickness in healthy human aging. Brain Struct. Funct. 226, 2839 (2021).","journal-title":"Brain Struct. Funct."},{"key":"820_CR24","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1152\/jn.00102.2009","volume":"102","author":"K Amano","year":"2009","unstructured":"Amano, K., Wandell, B. A. & Dumoulin, S. O. Visual field maps, population receptive field sizes, and visual field coverage in the human MT+ complex. J. Neurophysiol. 102, 2704 (2009).","journal-title":"J. Neurophysiol."},{"key":"820_CR25","doi-asserted-by":"publisher","unstructured":"Pais M. L. et al. Rapid effects of tryptamine psychedelics on perceptual distortions and early visual cortical population receptive fields. Neuroimage 297 https:\/\/doi.org\/10.1016\/j.neuroimage.2024.120718 (2024).","DOI":"10.1016\/j.neuroimage.2024.120718"},{"key":"820_CR26","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","volume":"128","author":"AM Maguire","year":"2021","unstructured":"Maguire, A. M. et al. Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years. Ophthalmology 128, 1460\u20131468 (2021).","journal-title":"Ophthalmology"},{"key":"820_CR27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire, A. M. et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology 126, 1273\u20131285 (2019).","journal-title":"Ophthalmology"},{"key":"820_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","volume":"130","author":"K Stingl","year":"2023","unstructured":"Stingl, K. et al. Full-field scotopic threshold improvement after voretigene neparvovec-rzyl treatment correlates with chorioretinal atrophy. Ophthalmology 130, 764\u2013770 (2023).","journal-title":"Ophthalmology"},{"key":"820_CR29","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.2147\/OPTH.S231804","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao, J., Hussain, R. M. & Weng, C. Y. Voretigene neparvovec in retinal diseases: a review of the current clinical evidence. Clin. Ophthalmol. 14, 3855\u20133869 (2020).","journal-title":"Clin. Ophthalmol."},{"key":"820_CR30","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00417-021-05508-2","volume":"260","author":"C Deng","year":"2022","unstructured":"Deng, C. et al. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis. Graefes Arch. Clin. Exp. Ophthalmol. 260, 1543\u20131550 (2022).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"820_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1350-9462(00)00030-6","volume":"20","author":"GE Holder","year":"2001","unstructured":"Holder, G. E. Pattern electroretinography (PERG) and an integrated approach to visual pathway diagnosis. Prog. Retin Eye Res. 20, 531\u2013561 (2001).","journal-title":"Prog. Retin Eye Res."},{"key":"820_CR32","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3349\/ymj.2022.63.7.701","volume":"63","author":"JJ Kwak","year":"2022","unstructured":"Kwak, J. J., Kim, H. R. & Byeon, S. H. Short-term outcomes of the first in vivo gene therapy for RPE65-mediated retinitis pigmentosa. Yonsei Med. J. 63, 701 (2022).","journal-title":"Yonsei Med. J."},{"key":"820_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41433-023-02636-3","volume":"38","author":"LF Shi","year":"2023","unstructured":"Shi, L. F., Hall, A. J. & Thompson, D. A. Full-field stimulus threshold testing: a scoping review of current practice. Eye 38, 33\u201353 (2023).","journal-title":"Eye"},{"key":"820_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10384-012-0137-4","volume":"56","author":"N Chiba","year":"2012","unstructured":"Chiba, N., Imasawa, M., Goto, T., Imai, M. & Iijima, H. Foveal sensitivity and visual acuity in macular thickening disorders. Jpn J. Ophthalmol. 56, 375\u2013379 (2012).","journal-title":"Jpn J. Ophthalmol."},{"key":"820_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1162\/jocn.1991.3.4.329","volume":"3","author":"R Whitehead","year":"1991","unstructured":"Whitehead, R. Right hemisphere processing superiority during sustained visual attention. J. Cogn. Neurosci. 3, 329\u2013334 (1991).","journal-title":"J. Cogn. Neurosci."},{"key":"820_CR36","doi-asserted-by":"crossref","unstructured":"Hellige, J. B. Hemispheric asymmetry for visual information processing. Acta Neurobiol. Exp. 56, 485\u2013497 (1996).","DOI":"10.55782\/ane-1996-1151"},{"key":"820_CR37","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.ophtha.2017.01.029","volume":"124","author":"M Ashtari","year":"2017","unstructured":"Ashtari, M. et al. The role of the human visual cortex in assessment of the long-term durability of retinal gene therapy in follow-on RPE65 clinical trial patients. Ophthalmology 124, 873 (2017).","journal-title":"Ophthalmology"},{"key":"820_CR38","doi-asserted-by":"publisher","first-page":"40344","DOI":"10.3389\/fnins.2013.00010","volume":"7","author":"K Hugdahl","year":"2013","unstructured":"Hugdahl, K. Visual-spatial information processing in the two hemispheres of the brain is dependent on the feature characteristics of the stimulus. Front. Neurosci. 7, 40344 (2013).","journal-title":"Front. Neurosci."},{"key":"820_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1167\/14.12.19","volume":"14","author":"MF Silva","year":"2014","unstructured":"Silva, M. F., d\u2019Almeida, O. C., Oliveiros, B., Mateus, C. & Castelo-Branco, M. Development and aging of visual hemifield asymmetries in contrast sensitivity. J. Vis. 14, 19 (2014).","journal-title":"J. Vis."},{"key":"820_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuropsychologia.2010.11.002","volume":"49","author":"J Sampaio","year":"2011","unstructured":"Sampaio, J. et al. Specific impairment of visual-spatial covert attention mechanisms in Parkinson\u2019s disease. Neuropsychologia 49, 34\u201342 (2011).","journal-title":"Neuropsychologia"},{"key":"820_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/10.6.26","volume":"10","author":"MF Silva","year":"2010","unstructured":"Silva, M. F. et al. Asymmetry of visual sensory mechanisms: electrophysiological, structural, and psychophysical evidences. J. Vis. 10, 26 (2010).","journal-title":"J. Vis."},{"key":"820_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.visres.2007.10.018","volume":"48","author":"MF Silva","year":"2008","unstructured":"Silva, M. F. et al. Retinal and cortical patterns of spatial anisotropy in contrast sensitivity tasks. Vis. Res. 48, 127\u2013135 (2008).","journal-title":"Vis. Res."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00820-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00820-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00820-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T22:43:28Z","timestamp":1744238608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00820-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["820"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-00820-y","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}